Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
A phase 3 trial of Acalabrutinib and Ibrutinib in chronic lymphocytic leukaemia, run by Acerta Pharma BV, active and no longer recruiting.
Overview
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) is a phase 3 interventional study registered as NCT02477696 by Acerta Pharma BV, with 533 participants enrolled, started 2015-07-28 and due to reach its primary completion in 2020-09-15. Interventions recorded: Acalabrutinib and Ibrutinib. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca and the tag pipeline.
- TrialA Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca and the tag pipeline.
- TrialA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca and the tag pipeline.
- TrialStudy of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca and the tag pipeline.
- TrialPhase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca and the tag pipeline.
- TrialAn Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia
Shares Acalabrutinib, AstraZeneca and the tag pipeline.
- TrialA Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca and the tag pipeline.
- TrialA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Shares Ibrutinib, Chronic lymphocytic leukaemia and the tag pipeline.